Search

Displaying results 4921 - 4930 of 10000 in total
  1. Drug

    RGX-121

    go.drugbank.com/drugs/DB17681
    Investigational

    RGX-121 is designed to use the NAV AAV9 vector to deliver the human iduronate-2-sulfatase gene to the central nervous system.

  2. Drug

    Beraprost

    go.drugbank.com/drugs/DB05229
    Investigational

    Beraprost is a synthetic analogue of prostacyclin, under clinical trials for the treatment of pulmonary hypertension. It is also being studied for use in avoiding reperfusion injury.

  3. Drug

    Marimastat

    go.drugbank.com/drugs/DB00786
    Investigational

    Used in the treatment of cancer, Marmiastat is an angiogenesis and metastasis inhibitor. As an angiogenesis inhibitor it limits the growth and production of blood vessels. … As an antimetatstatic agent it prevents malignant cells from breaching the basement membranes.

  4. Drug

    PZM21

    go.drugbank.com/drugs/DB14030
    Experimental

    PZM21 is a novel μ-opioid receptor (MOPr) ligand that has been reported to induce minimal arrestin recruitment and be devoid of the respiratory depressant effects characteristic of classical μ-opioid ligands

  5. Drug

    Bilastine

    go.drugbank.com/drugs/DB11591
    Approved

    Bilastine is a novel new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and prolonged duration of action.

  6. Drug

    AVAC

    go.drugbank.com/drugs/DB05441
    Experimental

    [Mycobacterium vaccae] is a non-pathogenic, saprophytic bacteria whose antigens can be used to induce peripheral immune activation through the activity of regulatory T-cells that surpress inappropriate … It has been tested in uses related to asthma and in treating eczema and atopic dermatitis.

  7. Drug

    Epofolate

    go.drugbank.com/drugs/DB12266
    Investigational

    Epofolate (BMS-753493) is a folate conjugate of the epothilone analog BMS-748285 that was designed to selectively target folate receptor expressing cancer cells. … and neutropenia appear to have been less frequent and less severe as compared to epothilones.

  8. Drug

    CYT006-AngQb

    go.drugbank.com/drugs/DB05739
    Investigational

    It is a unique treatment modality that aims to address the issue of patient compliance by offering convenient dosing schedules due to the long-lasting effect induced by vaccination. … It is designed to instruct the patient’s immune system to produce an antibody response against angiotensin II, a small peptide that causes blood vessels to narrow and results in increased blood pressure

  9. Drug

    Ebastine

    go.drugbank.com/drugs/DB11742
    ApprovedInvestigationalWithdrawn

    Ebastine is under investigation for the treatment of Irritable Bowel Syndrome (IBS). Ebastine has been investigated for the treatment of Urticaria.

  10. Drug

    ATN-161

    go.drugbank.com/drugs/DB05491
    Investigational

    expected to extend to a variety of cancers. … This approach targeting both the tumor vasculature and the cancer cells themselves, may be effective in single therapy as well as combination therapy.